Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens.
Bladder cancer
immunotherapy
neoadjuvant chemotherapy
prognosis
tumor microenvironment
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
15
05
2019
revised:
10
07
2019
accepted:
12
07
2019
entrez:
25
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
In patients with muscle invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) prior to radical cystectomy has improved survival but there is an urgent unmet need to identify prognostic and predictive biomarkers to stratify patients who will benefit from treatment. This study aimed to examine the composition of tumor-infiltrating immune cells in MIBC, with particular reference to the clinical outcome and the potential modifying effect of NAC. To this end, the expression of CD8
Identifiants
pubmed: 31646091
doi: 10.1080/2162402X.2019.1644108
pii: 1644108
pmc: PMC6791444
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1644108Informations de copyright
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Oncotarget. 2017 Aug 3;8(40):66849-66864
pubmed: 28978000
Cancers (Basel). 2014 Apr 23;6(2):969-97
pubmed: 24762633
Urology. 2015 Mar;85(3):703.e1-6
pubmed: 25733301
Mod Pathol. 2018 Feb;31(2):214-234
pubmed: 29192647
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Oncoimmunology. 2018 Jul 23;7(9):e1476816
pubmed: 30228944
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncoimmunology. 2018 Aug 1;7(9):e1474317
pubmed: 30393586
Cancer Immunol Immunother. 2019 Jan;68(1):45-56
pubmed: 30259082
Trends Cancer. 2016 Dec;2(12):747-757
pubmed: 28626801
Clin Genitourin Cancer. 2016 Apr;14(2):183-7
pubmed: 26775720
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Oncoimmunology. 2016 Feb 18;5(5):e1134412
pubmed: 27467953
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Adv Urol. 2013;2013:317190
pubmed: 24382958
Eur Urol. 2018 Dec;74(6):688-692
pubmed: 30025882
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Mod Pathol. 2018 Apr;31(4):623-632
pubmed: 29271413
Oncogenesis. 2018 Jan 23;7(1):2
pubmed: 29358573
Urol Oncol. 2019 May;37(5):299.e19-299.e25
pubmed: 30660491
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Oncotarget. 2016 Aug 23;7(34):55828-55839
pubmed: 27331871
Sci Rep. 2018 May 10;8(1):7485
pubmed: 29748589
PLoS One. 2018 Oct 11;13(10):e0205746
pubmed: 30308033
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Bladder Cancer. 2018 Jul 30;4(3):327-337
pubmed: 30112444
Bladder Cancer. 2018 Jan 20;4(1):1-7
pubmed: 29430502
Eur Urol. 2016 Mar;69(3):438-47
pubmed: 26508308
Int J Cancer. 2016 Sep 1;139(5):1129-39
pubmed: 27074317
Cancer Immunol Res. 2018 May;6(5):528-538
pubmed: 29588320
Oncotarget. 2017 Jul 18;8(38):64066-64082
pubmed: 28969052
Bladder Cancer. 2016 Oct 27;2(4):425-432
pubmed: 28035323
Nat Rev Urol. 2018 Feb;15(2):92-111
pubmed: 29133939
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Nat Immunol. 2006 Apr;7(4):344-53
pubmed: 16550197
Investig Clin Urol. 2018 Sep;59(5):285-296
pubmed: 30182073
Bladder Cancer. 2017 Oct 27;3(4):259-267
pubmed: 29152550
N Engl J Med. 1990 Apr 19;322(16):1129-38
pubmed: 2181313
Med Oncol. 2017 Sep 1;34(10):170
pubmed: 28864844
Oncotarget. 2015 Sep 22;6(28):26065-78
pubmed: 26305549
Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310
pubmed: 30083254
Clin Immunol. 2017 Mar;176:63-70
pubmed: 28025135
Expert Rev Anticancer Ther. 2015;15(8):943-54
pubmed: 26098949
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Oncotarget. 2017 Dec 22;9(4):5058-5072
pubmed: 29435162
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033